Complicated Disease Course
Introduction
A complicated disease course refers to a medical condition that deviates significantly from its typical or expected progression, often characterized by increased severity, resistance to standard treatments, unpredictable exacerbations, or the development of serious comorbidities. This complexity can arise from a multitude of interacting factors, including an individual's unique genetic makeup, environmental exposures, and lifestyle choices. Understanding the underlying mechanisms contributing to a complicated disease course is crucial for effective patient management and the development of targeted therapies.
Biological Basis
The biological underpinnings of a complicated disease course are often rooted in genetic variations, particularly single nucleotide polymorphisms (SNPs), which can influence various physiological processes. These genetic differences can affect an individual's susceptibility to a disease, the severity of its symptoms, and how they respond to treatment. For instance, SNPs can impact immune system regulation, drug metabolism pathways, cellular repair mechanisms, or the expression of genes involved in inflammation or tissue damage. Genome-Wide Association Studies (GWAS) are instrumental in identifying genetic loci associated with disease susceptibility and progression. [1] By analyzing hundreds of thousands of SNPs across the genome, researchers can pinpoint variants that contribute to a more complex disease trajectory. [2] Such studies often involve stringent quality control measures, including filtering SNPs based on call rates, minor allele frequencies, and adherence to Hardy-Weinberg equilibrium, to ensure the reliability of identified associations. [3] The interplay between multiple SNPs, sometimes across different genes, can lead to epistatic interactions that further complicate disease outcomes. [4]
Clinical Relevance
From a clinical perspective, identifying factors that predispose individuals to a complicated disease course is paramount for personalized medicine. Genetic insights can enable clinicians to stratify patients based on their risk of experiencing severe or refractory disease, allowing for earlier intervention, more aggressive monitoring, or the selection of alternative treatment strategies. For example, knowing a patient's genetic profile might inform decisions about drug dosage, predict adverse reactions, or indicate a higher likelihood of disease recurrence. This proactive approach can significantly improve patient outcomes, reduce healthcare burden, and enhance the quality of life for those affected.
Social Importance
The societal impact of complicated disease courses is substantial, affecting public health, healthcare economics, and individual well-being. Diseases with unpredictable and severe trajectories place a greater demand on healthcare resources, including prolonged hospitalizations, specialized treatments, and long-term care. Furthermore, individuals experiencing a complicated course often face significant challenges to their quality of life, including chronic pain, disability, and psychological distress. By unraveling the genetic and biological basis of these complexities, research can pave the way for preventative strategies, more effective treatments, and ultimately reduce the overall burden of disease on society. This knowledge also contributes to a deeper understanding of human health and disease, fostering innovation in medical science.
Methodological and Statistical Constraints
Many genome-wide association studies (GWAS) face inherent limitations related to study design and statistical power, which can impact the detection and interpretation of genetic associations for complicated disease courses. Modest sample sizes, particularly for relatively rare or clinically defined diseases, often result in limited power to detect variants with small to moderate effect sizes, meaning many true associations might not reach genome-wide significance. [5] This limitation is compounded by the phenomenon of effect-size inflation, where significant loci from initial genome-wide studies tend to have overestimated effects, leading to a decrease in the observed association strength in subsequent replication efforts. [6]
Furthermore, the stringent statistical thresholds required for genome-wide significance, while crucial for reducing false positives, can increase false negative rates, potentially masking true associations of moderate effect size. [1] Replication studies, essential for confirming initial findings, also require comparably large sample sizes, and a failure to replicate in smaller cohorts does not necessarily rule out a true association due to insufficient power in the replication phase. [5] Technical issues such as genotyping errors, imperfect genotype calling, and limitations in assay design can also introduce spurious associations or lead to the exclusion of potentially relevant variants. [5]
Genomic Coverage and Phenotype Heterogeneity
The scope of genetic investigations can be restricted by limitations in genomic coverage and the complexity of disease phenotypes. Many genotyping platforms, by design, offer incomplete coverage of common genetic variation and often poorly represent rare variants, including structural variants, which can limit the power to detect highly penetrant alleles. [5] This incomplete coverage, coupled with the inherent difficulties in defining the full genomic extent of disease-associated genes, means that current association signals often define regions of interest rather than unambiguously identifying the specific causal genes. [5] Extensive resequencing and fine-mapping are frequently required to pinpoint the precise functional variants.
Furthermore, the clinical definition and measurement of complex diseases can introduce heterogeneity that complicates genetic analysis. Diseases like chronic obstructive pulmonary disease (COPD) are inherently heterogeneous, and even with standardized spirometry-based definitions, variations in phenotype expression can mask underlying genetic effects. [7] Concerns regarding sample ascertainment and diagnostic criteria for diseases such as Alzheimer's disease underscore the importance of precise phenotyping, as inconsistencies can lead to biases and limit the generalizability of findings. [6]
Population and Environmental Influences
Genetic association studies are also susceptible to biases related to population structure and the complex interplay of genes and environment. Differences in ancestry between case and control cohorts can lead to spurious associations if not rigorously controlled for, although careful analysis can mitigate this risk. [5] The generalizability of findings can be limited if studies are predominantly conducted in populations of similar ethnicity, highlighting the need for diverse cohorts to ensure that identified variants are relevant across different ancestral backgrounds. [8]
Beyond genetic factors, environmental or gene-environment confounders represent a significant challenge in fully explaining disease heritability. While studies may adjust for known covariates such as APOE status, age, and sex, the vast array of unmeasured environmental exposures and lifestyle factors can influence disease risk and progression, contributing to the "missing heritability" phenomenon. [3] Disentangling these complex interactions requires sophisticated study designs and comprehensive data collection beyond genetic markers alone, representing a substantial remaining knowledge gap in understanding the complete etiology of complicated diseases.
Variants
The genetic variant *rs11924265* is associated with the MAGI1 gene, which encodes a scaffolding protein known as Membrane Associated Guanylate Kinase Inverted 1. MAGI1 plays a crucial role in maintaining cell polarity and cell-cell junctions, particularly in epithelial tissues like the kidney and brain, where it helps form tight junctions and adherens junctions. These functions are essential for tissue integrity and barrier function, impacting diverse biological processes from nutrient transport to immune surveillance. Alterations in MAGI1 activity due to variants like *rs11924265* could disrupt these critical cellular structures, potentially leading to increased tissue permeability or impaired signaling pathways, which may contribute to the development or complicated course of various diseases, including kidney disorders and neurological conditions. [9] For instance, dysfunctional cell junctions are implicated in inflammatory bowel diseases and certain neurodegenerative conditions, highlighting the broad impact of MAGI1 integrity. [10]
Another variant, *rs12122337*, is associated with CFAP45 (Cilia And Flagella Associated Protein 45), a gene vital for the proper assembly and function of cilia and flagella. These hair-like organelles extend from cell surfaces and are essential for cell motility, sensory perception, and fluid movement in many tissues, including the respiratory tract, kidneys, and brain. Variants in CFAP45, such as *rs12122337*, can disrupt ciliary structure or function, leading to a group of genetic disorders known as ciliopathies. These conditions are characterized by a wide array of symptoms affecting multiple organ systems, including polycystic kidney disease, retinal degeneration, and brain malformations, often presenting with complex and overlapping traits. [11] Such genetic variations can result in a complicated disease course due to the systemic nature of ciliary dysfunction, impacting developmental processes and homeostatic maintenance throughout life. [1]
The TAGLN2 gene, also known as Transgelin 2, encodes an actin-binding protein that is involved in regulating cell shape, motility, and cytoskeletal organization. TAGLN2 plays a role in various cellular processes, including smooth muscle contraction, immune cell function, and cell migration, making it a key player in tissue remodeling and inflammatory responses. Genetic variations affecting TAGLN2 could alter the dynamic properties of the actin cytoskeleton, influencing cell stiffness, adhesion, and movement. These changes might contribute to the pathogenesis or progression of diseases involving uncontrolled cell proliferation or chronic inflammation, such as certain cancers or cardiovascular conditions. [12] Furthermore, its involvement in immune cell function suggests that variants in TAGLN2 could modify immune responses, potentially influencing susceptibility to autoimmune diseases or the severity of infectious processes. [13]
Key Variants
| RS ID | Gene | Related Traits |
|---|---|---|
| rs11924265 | MAGI1 | complicated disease course stricture, Crohn's disease |
| rs12122337 | CFAP45 - TAGLN2 | complicated disease course |
Defining Disease States and Diagnostic Criteria
The accurate characterization of disease states necessitates precise operational definitions and robust diagnostic criteria, which often integrate clinical observations with objective measurements. Many diseases, such as heart failure, rely on the concurrent presence of specific clinical manifestations, often distinguished as major and minor criteria, to establish a diagnosis . A definitive indicator, or pathognomonic sign, is the presence of coronary artery damage identified through echocardiography, which can allow for diagnosis even with fewer classical criteria. [1] However, to maintain research cohort homogeneity, cases of "incomplete KD," where patients exhibit fever and fewer than four criteria without coronary artery manifestations, are typically excluded. [1]
Chronic Obstructive Pulmonary Disease (COPD) is characterized by a spirometry-based definition, allowing for the classification of individuals across a spectrum of disease severity. [7] Severely affected patients within these cohorts are often of particular interest, as they may exhibit an enrichment of specific susceptibility genes. [7] Similarly, Inflammatory Bowel Disease (IBD) encompasses distinct clinical phenotypes, such as Crohn's disease and ulcerative colitis, with diagnoses made according to standard IBD criteria, including specific considerations for early-onset cases. [14]
Diagnostic Approaches and Objective Assessment
Accurate diagnosis of complex diseases requires a combination of assessment methods, integrating objective and subjective measures. In Kawasaki Disease, there is no single diagnostic test, and individual laboratory parameters often lack sufficient sensitivity or specificity for a definitive diagnosis. [1] Instead, diagnosis relies on a thorough collection of clinical symptoms and laboratory data obtained directly from patient medical files, supplemented by information gathered through parental questionnaires, with all phenotypic data meticulously reviewed by experienced pediatricians. [1]
In contrast, Chronic Obstructive Pulmonary Disease (COPD) utilizes spirometry as a key objective measurement to define the disease and assess its progression. [7] For the diagnosis of psychotic illnesses, the OPCRIT diagnostic system provides a structured framework for applying operational criteria, ensuring consistency in classification. [5] These diverse diagnostic tools highlight the necessity of employing both standardized objective measures and expert clinical judgment to characterize complicated disease courses accurately.
Disease Heterogeneity and Diagnostic Significance
The course of many complex diseases is marked by considerable heterogeneity, which significantly impacts diagnostic strategies and prognostic indicators. Chronic Obstructive Pulmonary Disease, for example, is recognized as a highly heterogeneous condition, presenting with varied clinical patterns among individuals. [7] This phenotypic diversity contributes to the inconsistent results often observed in genetic association studies across different complex diseases. [7] Strategies such as maximizing phenotypic homogeneity in research cohorts, like excluding incomplete Kawasaki Disease cases, are employed to improve the statistical power and reduce the risk of spurious genetic associations. [1]
Despite the inherent complexities, understanding these varied presentation patterns and their genetic underpinnings holds crucial diagnostic and prognostic significance. While the current ability to provide clinically useful disease prediction based solely on identified genetic variants remains limited [5] the identification of severely affected individuals in disease cohorts can be diagnostically informative. These subgroups may be enriched for specific disease susceptibility genes, offering valuable insights into the genetic architecture of the disease and potentially guiding the development of more targeted diagnostic tools and therapeutic interventions. [7]
Causes
A complicated disease course often stems from a confluence of genetic predispositions, environmental exposures, and the complex interactions between them. Genome-wide association studies (GWAS) have significantly advanced the understanding of the genetic underpinnings of many complex diseases, revealing a multifaceted architecture that dictates disease progression and severity.
Polygenic and Inherited Risk
The genetic architecture underlying a complicated disease course is frequently polygenic, involving numerous common variants, each contributing a small effect to overall susceptibility. Research indicates that many common variants are associated with complex diseases, rapidly expanding knowledge of these traits' genetic basis. [8] For instance, Crohn's disease, a common inflammatory bowel disease, exhibits high heritability, with a lambda-s value of approximately 20-35, suggesting a strong inherited component to its development and progression. [8] This polygenic nature means that an individual's overall genetic risk is a cumulative effect of these many variants, rather than a single causative gene.
Specific Genetic Loci and Gene Interactions
Beyond a general polygenic risk, specific genetic loci and gene variants have been identified that contribute to the complexity of disease courses. These discoveries have illuminated new pathogenic mechanisms, such as the critical roles of autophagy and innate immunity in inflammatory bowel disease (IBD) pathogenesis . [8], [15] For example, variants in genes like IRGM, NOD2, ATG16L1, SLC22A4, SLC22A5, and NELL1 have been systematically associated with Crohn's disease susceptibility . [8], [10], [15], [16] Furthermore, genetic associations are often shared across different auto-inflammatory conditions, such as IL23R variants being linked to psoriasis and ankylosing spondylitis, and PTPN2 variants with type 1 diabetes. [8] While some identified genes may affect similar or overlapping pathways, studies in complex diseases like Crohn's have not found strong evidence of deviation from a model of multiplicative (random) effects when testing for gene-gene interactions among confirmed associations. [8]
Environmental and Host-Microbe Dynamics
Environmental factors, particularly those influencing host-microbe interactions, can significantly modulate the course of complex diseases. A notable example is the implication of dysregulated host-bacterial interactions in the pathogenesis of Crohn's disease. [8] This suggests that while genetic susceptibility provides the underlying framework, the specific composition and interaction with the gut microbiome, an environmental factor, can trigger or exacerbate the disease, leading to a more complicated course. The interaction between a genetically predisposed host and its microbial environment highlights how external elements can directly influence disease manifestation and progression.
Genetic Underpinnings and Gene Expression Regulation
The genetic architecture underlying complicated disease courses often involves multiple susceptibility loci, identified through genome-wide association studies (GWAS), which highlight common genetic variations contributing to disease pathogenesis. [8] These studies pinpoint specific genes and genomic regions, such as the MRAS gene and the HNF1A-C12orf43 region, which have been associated with conditions like coronary artery disease. [12] Similarly, genes like CSMD1, which encodes a multiple domain complement-regulatory protein highly expressed in the central nervous system and epithelial tissues, and NELL1, identified as a novel inflammatory bowel disease (IBD) gene with tissue-specific expression patterns, demonstrate the diverse genetic contributions to complex diseases. [1]
Beyond identifying specific genes, genetic mechanisms also involve the regulation of gene expression patterns. For instance, studies on Kawasaki disease have revealed significant differential gene mRNA transcript abundance in blood-expressed genes during the acute phase compared to convalescence, indicating dynamic changes in gene activity throughout the disease course . Furthermore, gene expression patterns in blood leukocytes are capable of discriminating patients with acute infections, indicating the dynamic and specific immune responses at play . This highlights the role of cellular machinery in maintaining gut barrier integrity and responding to microbial threats, where an enzyme like APEH (APH), a serine peptidase, helps degrade bacterial peptide breakdown products in the gut to prevent excessive immune responses . Specific variants in genes like IL2 and IL21 are implicated in T cell activation, a generic process crucial for autoimmune disorders, and variations in IL18RAP and IL23R are associated with shared susceptibility across celiac disease, Crohn's disease, psoriasis, and ankylosing spondylitis. [17] The IL-18 system also plays a role in cardiovascular disease, indicating broader relevance for inflammatory cytokines. [18]
Furthermore, pathways involving autophagy, such as the autophagy gene IRGM, and innate immunity are critical determinants of host-bacterial interactions in Crohn's disease, highlighting how cellular processes contribute to immune dysregulation. [19] Proteins like macrophage stimulatory protein 1 (MST1) are involved in inflammation and tissue remodeling, while APEH functions in the degradation of bacterial peptides to prevent excessive immune responses in the gut, thereby maintaining epithelial defense mechanisms. [4] The CD69 antigen, an early T-cell activation marker, and various CLEC (C-type lectin domain family) genes also suggest their involvement in modulating immune cell activity and inflammatory responses. [5]
Metabolic Regulation and Energy Homeostasis
Metabolic pathways are fundamental to cellular function and their dysregulation contributes significantly to disease. Energy metabolism, including mitochondrial function, is consistently implicated in neurodegenerative conditions such as Parkinson's disease, where transcriptional analyses reveal altered energy pathways. [20] The evolutionarily conserved insulin/insulin-like growth factor (IGF-1) signaling pathway is a key regulator of lifespan and healthy aging, with reduced signaling correlating with human longevity. [21]
Genetic variations, such as those in the SIRT3 gene, a human silent information regulator Sir2 homologue, have been linked to survivorship in the elderly, indicating the role of sirtuins in metabolic health and aging. [22] The microsomal transfer protein (MTP) has also been investigated for its potential association with human lifespan, highlighting lipid metabolism's impact on longevity. [23] Type 2 diabetes, a chronic metabolic disorder, exemplifies how systemic metabolic dysregulation, particularly involving glucose and lipid processing, drives complex disease progression. [5]
Protein Homeostasis and Cellular Stress Responses
Maintaining protein homeostasis is critical for cellular health, and disruptions can lead to the accumulation of misfolded proteins and cellular stress. In neurodegenerative diseases like Parkinson's, specific protein processing pathways are significantly implicated, including the endocytic pathway where a novel AAK1 splice variant functions at multiple steps. [20] Lysosomal function is also essential, with cyclin G associated kinase regulating lysosomal enzyme sorting and cathepsin D being the primary enzyme for degrading alpha-synuclein, a protein central to Parkinson's pathology. [24]
Endoplasmic reticulum (ER) stress signaling is a crucial mechanism in disease, particularly neurodegeneration, where the accumulation of misfolded proteins triggers cellular stress responses. [25] The ubiquitin pathway, involving genes like parkin, is fundamental for protein degradation and mutations in this pathway are known to cause autosomal recessive juvenile parkinsonism, demonstrating how protein quality control is vital for neuronal survival. [26] Additionally, pigmentation genes, such as those governing neuromelanin production in dopamine neurons, have been linked to Parkinson's disease, suggesting shared underlying etiologies with conditions like melanoma. [27]
Complex Signaling Cascades and Tissue Remodeling
Intricate signaling cascades govern cell behavior, tissue development, and repair, and their dysregulation contributes to various diseases. Presenilins, for example, mediate the activation of phosphatidylinositol 3-kinase (PI3K)/AKT and extracellular signal-regulated kinase (ERK) pathways through specific signaling receptors, with PS2 showing selectivity in platelet-derived growth factor signaling. [28] Similarly, B-cell receptor (BCR) mediated signal transduction is vital for B cell development and function, impacting immune responses. [29]
The Transforming Growth Factor-beta (TGF-beta) signaling pathway, utilizing Smad proteins, is crucial for transcriptional control and tissue remodeling, with Smad3 allostery linking receptor kinase activation to gene expression. [30] Impaired TGF-beta/Smad signaling in smooth muscle cells is observed in atherosclerotic lesions, demonstrating its role in cardiovascular disease pathogenesis and cell cycle regulation, as p15INK4B is an effector of TGF-beta-induced cell cycle arrest. [31] Furthermore, the GAB2 gene modifies Alzheimer's risk in APOE epsilon4 carriers, illustrating how upstream adaptor proteins integrate diverse signaling pathways to influence disease susceptibility. [32]
Stratifying Risk and Predicting Disease Trajectory
Understanding the genetic underpinnings of a complicated disease course is crucial for advanced risk stratification and prognostic assessment in patient care. Genome-wide association studies (GWAS) have identified specific genetic loci that influence susceptibility to various complex diseases, enabling the identification of individuals at higher risk even before symptom onset. [5] For instance, variants on chromosome 9p21 have been associated with an increased risk of myocardial infarction, providing a genetic marker for cardiovascular disease risk. [33] Such genetic insights can predict disease progression, as seen in Parkinson disease, where genetic factors are studied for their influence on the age of onset. [34]
Moreover, genetic information can offer prognostic value regarding long-term outcomes and treatment response. For conditions like chronic obstructive pulmonary disease (COPD), identifying susceptibility genes helps in understanding which individuals might be enriched for severe disease, thereby guiding early intervention and personalized management strategies. [7] Similarly, identifying genetic correlates for morbidity-free survival, such as being free of cardiovascular disease, dementia, and cancer at age 65, provides powerful prognostic indicators for healthy aging and highlights long-term implications of genetic predispositions. [35] This allows for tailored prevention strategies and more accurate counseling on potential long-term health trajectories.
Enhancing Diagnostic Approaches and Guiding Therapeutic Decisions
Genetic discoveries play a pivotal role in refining diagnostic utility and informing treatment selection for complex diseases. The identification of specific risk loci, such as a chromosome 12 locus for late-onset Alzheimer disease, can contribute to more precise diagnostic assessments, especially in cases with unclear clinical presentations. [3] While genetic prediction of disease is still evolving, the goal is to provide clinically useful prediction to aid in early diagnosis and intervention. [5]
Beyond diagnosis, genetic insights can guide therapeutic decisions and monitoring strategies. For example, understanding the impact of specific gene variants, such as those in the ABCB1 (MDR1) gene in inflammatory bowel disease, can inform clinicians about disease behavior and potentially predict response to certain treatments. [10] Furthermore, advanced techniques like gene expression analysis using Taqman low density arrays allow for investigating differential gene expression, which can be critical for monitoring disease activity or treatment efficacy in conditions like Kawasaki disease. [1] Such molecular monitoring complements traditional clinical assessments, offering a more nuanced understanding of disease dynamics.
Addressing Comorbidities and Disease Heterogeneity
A complicated disease course often involves the presence of multiple co-occurring conditions, or comorbidities, and significant heterogeneity in disease presentation. Genetic studies help elucidate these complex interrelationships, offering a more comprehensive view of patient health. Research has explicitly linked genetic factors to the presence of comorbidities like cardiovascular disease and cancer, highlighting shared genetic predispositions that influence overall morbidity. [35] This understanding is critical for managing patients with complex health profiles, as it suggests that a holistic approach considering multiple interconnected diseases may be more effective.
The recognition that conditions like COPD are heterogeneous diseases underscores the importance of genetic research in dissecting distinct underlying pathologies. [7] Genome-wide association studies are designed to detect variants that influence multiple phenotypes, shedding light on overlapping genetic architectures between seemingly distinct diseases or different manifestations of the same disease. [5] For instance, associations with different indices of renal function (eGFRcrea, eGFRcys) and chronic kidney disease are explored for their interrelationships, demonstrating how genetic studies can clarify the phenotypic spectrum and associations within disease categories. [36] This genetic perspective supports the development of personalized medicine approaches that account for the individual's unique genetic landscape and their propensity for various related conditions.
Frequently Asked Questions About Complicated Disease Course
These questions address the most important and specific aspects of complicated disease course based on current genetic research.
1. Why does my illness get worse, but my friend's stays mild?
Your unique genetic makeup plays a significant role in how a disease progresses. Genetic variations can influence everything from the severity of your symptoms to how your body responds to treatment, leading to different outcomes even with the same condition. Lifestyle and environment also interact with these genetic factors.
2. Will my kids inherit my unpredictable health problems?
Genetic predispositions for a complicated disease course can indeed be passed down through families. While it doesn't guarantee your children will experience the exact same issues, they might have a higher susceptibility to similar patterns of disease progression due to shared genetic variations.
3. Why don't my medications work as well as they do for others?
Your genetic profile can affect how your body metabolizes drugs and responds to specific treatments. These genetic differences can make certain medications less effective or even cause different side effects for you compared to someone else, requiring a more personalized approach to your care.
4. Can healthy eating stop my chronic condition from flaring up badly?
Yes, lifestyle choices like diet are crucial. While your genetic makeup can predispose you to a complicated disease course, environmental exposures and daily habits can significantly influence how your genes express themselves, potentially mitigating severe flare-ups or disease progression.
5. Would a genetic test help predict my severe symptoms?
Yes, understanding your genetic profile through tests like Genome-Wide Association Studies (GWAS) can help identify factors that predispose you to a more severe or resistant disease course. This information can enable clinicians to stratify your risk and tailor interventions more effectively.
6. Is it true stress makes my condition harder to manage?
Absolutely. Environmental factors and lifestyle choices, including stress levels, interact with your unique genetic makeup. This interplay can influence the regulation of your immune system and inflammation pathways, potentially complicating your disease course and making it harder to manage.
7. Does my condition always get worse as I get older?
Not necessarily. While some conditions naturally progress, your specific genetic variations and how they interact with your environment over time can influence the disease trajectory. Proactive management and personalized care based on your genetic insights can sometimes alter this progression.
8. Can my job environment affect my disease severity?
Yes, environmental exposures, including those encountered in your workplace, can interact with your genetic predispositions. This interaction can influence the expression of genes involved in inflammation or tissue damage, potentially contributing to a more complicated or severe disease course for you.
9. Can I really overcome my family history of severe illness?
While genetics play a significant role in susceptibility and severity, they are not the sole determinant. Lifestyle choices, early intervention, and personalized medical strategies informed by genetic insights can help you manage risks and potentially alter the trajectory of a complicated disease course, even with a strong family history.
10. Does my ethnic background affect my disease risk?
Yes, different populations often have varying frequencies of specific genetic variations (SNPs). Your ancestral background can therefore influence your susceptibility to certain diseases and how they might progress, making some ethnic groups more prone to complicated disease courses.
This FAQ was automatically generated based on current genetic research and may be updated as new information becomes available.
Disclaimer: This information is for educational purposes only and should not be used as a substitute for professional medical advice. Always consult with a healthcare provider for personalized medical guidance.
References
[1] Burgner D, et al. "A genome-wide association study identifies novel and functionally related susceptibility Loci for Kawasaki disease." PLoS Genet, vol. 5, no. 1, 2009, e1000319.
[2] Abraham, R. et al. "A genome-wide association study for late-onset Alzheimer's disease using DNA pooling." BMC Med Genomics, 2008.
[3] Beecham, G. W. et al. "Genome-wide association study implicates a chromosome 12 risk locus for late-onset Alzheimer disease." American Journal of Human Genetics, vol. 84, no. 1, 2009, pp. 65-74.
[4] Raelson JV, et al. "Genome-wide association study for Crohn's disease in the Quebec Founder Population identifies multiple validated disease loci." Proc Natl Acad Sci U S A, vol. 104, no. 38, 2007, pp. 15023–15028.
[5] Wellcome Trust Case Control Consortium. "Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls." Nature 447.7145 (2007): 661-678.
[6] Harold, D et al. "Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease." Nat Genet, 2009. PMID: 19734902.
[7] Pillai, S. G., et al. "A genome-wide association study in chronic obstructive pulmonary disease (COPD): identification of two major susceptibility loci." PLoS Genet 5.3 (2009): e1000421.
[8] Barrett JC, et al. "Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease." Nat Genet, vol. 40, no. 7, 2008, pp. 955–962.
[9] Larson, MG et al. "Framingham Heart Study 100K project: genome-wide associations for cardiovascular disease outcomes." BMC Med Genet, 2007. PMID: 17903304.
[10] Franke A, et al. "Systematic association mapping identifies NELL1 as a novel IBD disease gene." PLoS One, vol. 2, no. 8, 2007, e791.
[11] Garcia-Barcelo, MM et al. "Genome-wide association study identifies NRG1 as a susceptibility locus for Hirschsprung's disease." Proc Natl Acad Sci U S A, 2009. PMID: 19196962.
[12] Erdmann, J et al. "New susceptibility locus for coronary artery disease on chromosome 3q22.3." Nat Genet, 2009. PMID: 19198612.
[13] Pankratz, N et al. "Genomewide association study for susceptibility genes contributing to familial Parkinson disease." Hum Genet, 2008. PMID: 18985386.
[14] Imielinski, M. et al. “Common Variants at Five New Loci Associated with Early-Onset Inflammatory Bowel Disease.” Nature Genetics, 2009.
[15] Rioux, John D., et al. "Genome-wide association study identifies new susceptibility loci for Crohn disease and implicates autophagy in disease pathogenesis." Nature Genetics, vol. 39, no. 5, 2007, pp. 596-604.
[16] Fisher SA, Hampe J, Onnie CM, et al. "Direct or indirect association in a complex disease: the role of SLC22A4 and SLC22A5 functional variants in Crohn disease." Hum Mutat, vol. 27, 2006, pp. 778–785.
[17] Hunt KA, et al. "Newly identified genetic risk variants for celiac disease related to the immune response." Nat Genet, vol. 40, no. 3, 2008, pp. 314–320.
[18] Tiret L, Godefroy T, Lubos E, et al. "Genetic analysis of the interleukin-18 system highlights the role of the interleukin-18 gene in cardiovascular disease." Circulation, vol. 112, 2005, pp. 643–650.
[19] Parkes M, Barrett JC, Prescott NJ, et al. "Sequence variants in the autophagy gene IRGM and multiple other replicating loci contribute to Crohn’s disease susceptibility." Nat Genet, 2007.
[20] Zhang Y, James M, Middleton FA, et al. "Transcriptional analysis of multiple brain regions in Parkinson's disease supports the involvement of specific protein processing, energy metabolism, and signaling pathways, and suggests novel disease mechanisms." Am J Med Genet B Neuropsychiatr Genet, vol. 137B, no. 1, 2005, pp. 5–16.
[21] van Heemst D, Beekman M, Mooijaart SP, et al. "Reduced insulin/IGF-1 signalling and human longevity." Aging Cell, vol. 4, no. 2, 2005, p. 79.
[22] Rose G, Dato S, Altomare K, et al. "Variability of the SIRT3 gene, human silent information regulator Sir2 homologue, and survivorship in the elderly." Exp Gerontol, vol. 38, no. 10, 2003, p. 1065.
[23] Geesaman BJ, Benson E, Brewster SJ, et al. "Haplotype-based identification of a microsomal transfer protein marker associated with the human lifespan." Proc Natl Acad Sci U S A, vol. 100, no. 24, 2003, pp. 14115.
[24] Kametaka S, Moriyama K, Burgos PV, et al. "Canonical interaction of cyclin G associated kinase with adaptor protein 1 regulates lysosomal enzyme sorting." Mol Biol Cell, vol. 18, no. 8, 2007, pp. 2991–3001.
[25] Marciniak SJ, Ron D. "Endoplasmic reticulum stress signaling in disease." Physiol Rev, vol. 86, no. 4, 2006, pp. 1133–1149.
[26] Kitada T, Asakawa S, Hattori N, et al. "Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism." Nature, vol. 392, 1998, pp. 605–608.
[27] Fedorow H, Tribl F, Halliday G, et al. "Neuromelanin in human dopamine neurons: comparison with peripheral melanins and relevance to Parkinson's disease." Prog Neurobiol, vol. 75, no. 2, 2005, pp. 109–124.
[28] Kang DE, Yoon IS, Repetto E, et al. "Presenilins mediate phosphatidylinositol 3-kinase/AKT and ERK activation via select signaling receptors. Selectivity of PS2 in platelet-derived growth factor signaling." J Biol Chem, vol. 208, 2005, pp. 31537–31547.
[29] Koncz G, Bodor C, Kovesdi D, et al. "BCR mediated signal transduction in immature and mature B cells." Immunol Lett, vol. 82, 2002, pp. 41–49.
[30] Miyazono K. "TGF-beta signaling by Smad proteins." Cytokine Growth Factor Rev, vol. 11, 2000, pp. 15–22.
[31] Hannon GJ, Beach D. "p15INK4B is a potential effector of TGF-beta-induced cell cycle arrest." Nature, vol. 371, 1994, pp. 257–61.
[32] Reiman EM, et al. "GAB2 alleles modify Alzheimer’s risk in APOE epsilon4 carriers." Neuron, vol. 54, no. 5, 2007, pp. 713–720.
[33] Helgadottir A, Thorleifsson G, Manolescu A, et al. "A common variant on chromosome 9p21 affects the risk of myocardial infarction." Science, vol. 316, 2007, pp. 1491–3.
[34] Latourelle, J. C. "Genomewide association study for onset age in Parkinson disease." BMC Medical Genetics, vol. 10, 2009, p. 98.
[35] Lunetta KL, et al. "Genetic correlates of longevity and selected age-related phenotypes: a genome-wide association study in the Framingham Study." BMC Med Genet, vol. 8, 2007, p. 70.
[36] Kottgen, Anna, et al. "Multiple loci associated with indices of renal function and chronic kidney disease." Nature Genetics, vol. 41, no. 6, 2009, pp. 712-717.